Jiangsu Atom Bioscience & Pharmaceutical Co. Ltd (Atom Bioscience) has raised 150 million yuan ($22 million) in a Series B round led by Livzon Pharmaceutical, a wholly-owned investment platform Zhuhai Lizhu Pharmaceutical Equity Investment Management Co., Ltd. In a separate development, China’s premium big data solution company Chengdu Shuzhilian Technology Company has also secured a similar amount from GF Venture Capital and existing investor Yinxinggu Capital.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
